UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.__)*

 

Arch Therapeutics, Inc.
(Name of Issuer)

 

Common Stock
(Title of Class of Securities)

 

03939W208
(CUSIP Number)

 

July 12, 2023
(Date of Event Which Requires Filing of this Statement)

   

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)

 

Rule 13d-1(c)

 

Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No.______

 

(1) Names of reporting persons
  Brandt Wilson
   
(2) Check the appropriate box if a member of a group (see instructions)
  (a)
  (b) ☐
   
(3) SEC use only
   
   
(4) Citizenship or place of organization
  United States of America, Territory of Puerto Rico
   
  Number of shares beneficially owned by each reporting person with:
     
  (5) Sole voting power
    300,000
     
  (6) Shared voting power
    0
     
  (7) Sole dispositive power
    300,000
     
  (8) Shared dispositive power
    0
   
(9) Aggregate amount beneficially owned by each reporting person
  300,000
   
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
   
   
(10) Percent of class represented by amount in Row (9)
  9.89%1
   
(12) Type of reporting person (see instructions)
  Accredited Investors

 

 

1This percentage is calculated based upon approximately 3,034,458 shares of common stock of Arch Therapeutics Inc. (the “Company”). The number of outstanding common stock was furnished by the Company. Mr. Brandt Wilson as an individual is deemed to beneficially own 9.89% of common stock of the Company, as a result of Mr. Wilson’s equity purchase agreement, which gives Mr. Wilson the right to own an aggregate number of shares of the Company’s common stock in the amount not to exceed 9.99% of shares of common stock then outstanding.

 

2

 

 

ITEM 1(A) NAME OF ISSUER:

 

Arch Therapeutics, Inc.

 

ITEM 1(B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

 

235 Walnut Street, Suite 6, Farmingham, MA 01702

 

ITEM 2 (A) NAME OF PERSON FILING:

 

Brandt Wilson

 

ITEM 2 (B) ADDRESS OR PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

 

1101 Plantation VLG Dr, Dorado, Puerto Rico, 00646, USA

 

ITEM 2 (C) CITIZENSHIP:

 

United States of America

 

ITEM 2 (D) TITLE OF CLASS OF SECURITIES:

 

Common Stock

 

ITEM 2 (E) CUSIP NO.:

 

03939W208

 

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

 

(a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

 

(b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

 

(c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

 

(d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

 

(e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

 

(f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

 

(g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

 

(h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

(j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

 

(k) Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

 

3

 

 

ITEM 4. OWNERSHIP 

 

(a) Amount beneficially owned: 300,000
   
(b) Percent of class: 9.89%

 

(c) Number of shares as to which the person has:

 

  (i) Sole power to vote or to direct the vote 300,000
     
  (ii) Shared power to vote or to direct the vote 0
     
  (iii) Sole power to dispose or to direct the disposition of 300,000
     
  (iv) Shared power to dispose or to direct the disposition of 0

 

ITEM 5. OWNERSHIP OF 5 PERCENT OR LESS OF A CLASS.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

 

ITEM 6. OWNERSHIP OF MORE THAN 5 PERCENT ON BEHALF OF ANOTHER PERSON.

 

Not Applicable

 

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON.

 

Not Applicable

 

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

 

Not Applicable

 

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

 

Not Applicable

 

ITEM 10. CERTIFICATIONS

 

(a)The following certification shall be included if the statement is filed pursuant to § 240.13d-1(b):

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

  

(b)The following certification shall be included if the statement is filed pursuant to § 240.13d-1(c):

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

4

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  Dated: July 25, 2023
     
  Signature. /s/ Brandt Wilson
     
  Name/Title. As An Individual

 

5